ANTIKÖRPER GEGEN CSF-1R

European patent · EP3549599 · In force

Register entry

Publication number
EP3549599
Application number
EP19171833
Kind
European patent with effect for Switzerland and Liechtenstein
Status
In force
Specification
Granted
Filed
Aug 26, 2014
Published
Oct 9, 2019
Granted
Sep 6, 2023
Protection ends at the latest
Aug 25, 2034
Next annual fee due
Aug 31, 2027
IPC classes
A61K 39/00 (2006.01)
A61P 11/00 (2006.01)
A61P 35/00 (2006.01)
C07K 16/28 (2006.01)
Priority
GB 201315487 30.08.2013
Filing language
English
Source
Swissreg

History

What the Federal Institute of Intellectual Property published about this title, newest first.

  1. Sep 1, 2026

    Next annual fee due on

    Next annual fee due on
    31.08.2026 → 31.08.2027

    Published in Swissreg on 01.09.2026

  2. Sep 1, 2025

    Next annual fee due on

    Next annual fee due on
    31.08.2025 → 31.08.2026

    Published in Swissreg on 01.09.2025

  3. Sep 3, 2024

    Next annual fee due on

    Next annual fee due on
    31.08.2024 → 31.08.2025

    Published in Swissreg on 03.09.2024

  4. Jul 17, 2024

    Change

    Published in Swissreg on 17.07.2024

  5. Sep 6, 2023

    Granted

    Published in Swissreg on 06.09.2023

Parties

Holder

UCB Biopharma SRL

Allée de la Recherche 60, 1070 Brussels, BE

Inventor

HERVÉ, Karine Jeannine Madeleine

Slough, Berkshire SL1 3WE, GB

MARSHALL, Diane

Slough, Berkshire SL1 3WE, GB

CRAGGS, Graham

Slough, Berkshire SL1 3WE, GB

The register names each party by name and address. A holder or agent is linked to an organization where exactly one entity of the commercial register bears its name; the street of a party not so recognised is not shown here.